Month: April 2023
Replace on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Most cancers
April 28, 2023 5:30 pm ET RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), often known as MSD exterior of the US and Canada, right this moment introduced that the U.S. Meals and Drug Administration’s (FDA) Oncologic Medicine Advisory Committee (ODAC), by a vote of 11 to 1 with one abstention, supported FDA approval of LYNPARZA plus…
